WO2002081712A3 - Artificial chromosomes comprising ehv sequences - Google Patents

Artificial chromosomes comprising ehv sequences Download PDF

Info

Publication number
WO2002081712A3
WO2002081712A3 PCT/EP2002/003575 EP0203575W WO02081712A3 WO 2002081712 A3 WO2002081712 A3 WO 2002081712A3 EP 0203575 W EP0203575 W EP 0203575W WO 02081712 A3 WO02081712 A3 WO 02081712A3
Authority
WO
WIPO (PCT)
Prior art keywords
ehv
artificial chromosomes
equine
methods
sequences
Prior art date
Application number
PCT/EP2002/003575
Other languages
French (fr)
Other versions
WO2002081712A2 (en
Inventor
Nikolaus Osterrieder
Jens Rudolph
Original Assignee
Boehringer Ingelheim Vetmed
Nikolaus Osterrieder
Jens Rudolph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed, Nikolaus Osterrieder, Jens Rudolph filed Critical Boehringer Ingelheim Vetmed
Priority to CA002443039A priority Critical patent/CA2443039A1/en
Priority to MXPA03008971A priority patent/MXPA03008971A/en
Priority to EP02727508A priority patent/EP1377668A2/en
Priority to JP2002580075A priority patent/JP2004531254A/en
Publication of WO2002081712A2 publication Critical patent/WO2002081712A2/en
Publication of WO2002081712A3 publication Critical patent/WO2002081712A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention belongs to the field of animal health, in particular equine diseases caused by equine herpesvirus (EHV). The invention relates to artificial chromosomes comprising the genome of equine herpesviruses, methods of producing attenuated or virulent EHV with or without the insertion of foreign genes, EHV obtainable with said methods and pharmaceutical compositions comprising said viruses.
PCT/EP2002/003575 2001-04-03 2002-03-30 Artificial chromosomes comprising ehv sequences WO2002081712A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002443039A CA2443039A1 (en) 2001-04-03 2002-03-30 Artificial chromosomes comprising ehv sequences
MXPA03008971A MXPA03008971A (en) 2001-04-03 2002-03-30 Artificial chromosomes comprising ehv sequences.
EP02727508A EP1377668A2 (en) 2001-04-03 2002-03-30 Artificial chromosomes comprising ehv sequences
JP2002580075A JP2004531254A (en) 2001-04-03 2002-03-30 Artificial chromosome containing EHV sequence

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10116594.3 2001-04-03
DE2001116594 DE10116594A1 (en) 2001-04-03 2001-04-03 Artificial chromosomes comprising EHV sequences

Publications (2)

Publication Number Publication Date
WO2002081712A2 WO2002081712A2 (en) 2002-10-17
WO2002081712A3 true WO2002081712A3 (en) 2003-10-02

Family

ID=7680223

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/003575 WO2002081712A2 (en) 2001-04-03 2002-03-30 Artificial chromosomes comprising ehv sequences

Country Status (7)

Country Link
EP (1) EP1377668A2 (en)
JP (1) JP2004531254A (en)
AR (1) AR035809A1 (en)
CA (1) CA2443039A1 (en)
DE (1) DE10116594A1 (en)
MX (1) MXPA03008971A (en)
WO (1) WO2002081712A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080226677A1 (en) * 2004-05-06 2008-09-18 Yasuko Mori Recombinant virus vector for gene transfer into lymphoid cells
WO2013142371A1 (en) * 2012-03-20 2013-09-26 Merial Limited Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof
US10619169B2 (en) * 2016-09-20 2020-04-14 Boehringer Ingelheim Vetmedica Gmbh EHV insertion site ORF70

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6193983B1 (en) * 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6193983B1 (en) * 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
"RECOMBINANT HERPESVIRUSES LACKING GENE FOR GLYCOPROTEIN L", RESEARCH DISCLOSURE, KENNETH MASON PUBLICATIONS, HAMPSHIRE, GB, no. 371, 1 March 1995 (1995-03-01), pages 129 - 130, XP000512352, ISSN: 0374-4353 *
BRUNE W ET AL: "Forward with BACs - new tools for herpesvirus genomics", TRENDS IN GENETICS, ELSEVIER, AMSTERDAM, NL, vol. 16, no. 6, June 2000 (2000-06-01), pages 254 - 259, XP004200110, ISSN: 0168-9525 *
CSELLNER H ET AL: "EHV-1 glycoprotein D (EHV-1 gD) is required for virus entry and cell-cell fusion, and an EHV-1 gD deletion mutant induces a protective immune response in mice.", ARCHIVES OF VIROLOGY, vol. 145, no. 11, 2000, pages 2371 - 2385, XP002225300, ISSN: 0304-8608 *
FARRELL H E ET AL: "VACCINE POTENTIAL OF A HERPES SIMPLEX VIRUS TYPE 1 MUTANT WITH AN ESSENTIAL GLYCOPROTEIN DELETED", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 68, no. 2, 1 February 1994 (1994-02-01), pages 927 - 932, XP000650704, ISSN: 0022-538X *
FITZPATRICK D R STUDDERT M J: "IMMUNOLOGIC RELATIONSHIPS BETWEEN EQUINE HERPESVIRUS TYPE 1 (EQUINE ABORTION VIRUS) AND TYPE 4 (EQUINE RHINOPNEUMONITIS VIRUS)", AMERICAN JOURNAL OF VETERINARY RESEARCH, XX, XX, vol. 45, no. 10, 1 October 1984 (1984-10-01), pages 1947 - 1952, XP002053536, ISSN: 0002-9645 *
GRANOFF A, WEBSTER R G (EDS): "Encyclopedia of Virology", 1999, ACADEMIC PRESS, HARCOURT BRACE, SAN DIEGO, CA, USA, XP001121578 *
HÜBERT P H ET AL: "Alterations in the equine herpesvirus type-1 (EHV-1) strain RacH during attenuation.", ZENTRALBLATT FUR VETERINARMEDIZIN. REIHE B. JOURNAL OF VETERINARY MEDICINE. SERIES B. GERMANY MAR 1996, vol. 43, no. 1, March 1996 (1996-03-01), pages 1 - 14, XP001118934, ISSN: 0514-7166 *
HUTCHINSON L ET AL: "Herpes simplex virus glycoprotein K promotes egress of virus particles.", JOURNAL OF VIROLOGY. UNITED STATES SEP 1995, vol. 69, no. 9, September 1995 (1995-09-01), pages 5401 - 5413, XP002229844, ISSN: 0022-538X *
MARSHALL K R ET AL: "AN EQUINE HERPESVIRUS-1 GENE 71 DELETANT IS ATTENUATED AND ELICITS A PROTECTIVE IMMUNE RESPONSE IN MICE", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 231, no. 1, 1997, pages 20 - 27, XP002055348, ISSN: 0042-6822 *
MATSUMURA T ET AL: "An equine herpesvirus type 1 recombinant with a deletion in the gE and gI genes is avirulent in young horses.", VIROLOGY. UNITED STATES 1 MAR 1998, vol. 242, no. 1, 1 March 1998 (1998-03-01), pages 68 - 79, XP002229841, ISSN: 0042-6822 *
MATSUMURA T ET AL: "Lack of virulence of the murine fibroblast adapted strain, Kentucky A (KyA), of equine herpesvirus type 1 (EHV-1) in young horses", VETERINARY MICROBIOLOGY, AMSTERDAM, NL, vol. 48, no. 3-4, 1996, pages 353 - 365, XP002206317, ISSN: 0378-1135 *
MAYR A ET AL: "UNTERSUCHUNGEN ZUR ENTWICKLUNG EINES LEBENDIMPFSTOFFES GEGEN DIE RHINOPNEUMONITIS (STUTENABORT) DER PFERDE", JOURNAL OF VETERINARY MEDICINE. SERIES B - ZENTRALBLATT FUER VETERINAERMEDIZIN. REINE B, PAUL PAREY, BERLIN, DE, vol. 15, 1968, pages 406 - 418, XP000921173, ISSN: 0931-1793 *
MCGREGOR ALISTAIR ET AL: "Recent advances in Herpesvirus genetics using bacterial artificial chromosomes.", MOLECULAR GENETICS AND METABOLISM, vol. 72, no. 1, January 2001 (2001-01-01), pages 8 - 14, XP002213948, ISSN: 1096-7192 *
MESSERLE M ET AL: "Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 94, no. 26, 1 December 1997 (1997-12-01), pages 14759 - 14763, XP002086655, ISSN: 0027-8424 *
NEUBAUER A ET AL: "Analysis of the contributions of the equine herpesvirus 1 glycoprotein gB homolog to virus entry and direct cell-to-cell spread.", VIROLOGY. UNITED STATES 20 JAN 1997, vol. 227, no. 2, 20 January 1997 (1997-01-20), pages 281 - 294, XP002229840, ISSN: 0042-6822 *
NEUBAUER A ET AL: "DIE MUTATIONEN IM US2- UND GLYKOPROTEIN B-GEN DES EQUINEN HERPESVIRUS 1-IMPFSTAMMES RACH HABEN KEINEN EINFLUSS AUF SEINE ATTENUIERUNG MUTATIONS WITHIN THE US2 AND GLYCOPROTEIN B GEES OF THE EQUINE HERPESVIRUS 1 VACCINE STRAIN RACH DO NOT ACCOUNT FOR ITS", BERLINER UND MUENCHENER TIERAERZTLICHE WOCHENSCHRIFT, PAUL PAREY, BERLIN, DE, vol. 112, no. 9, September 1999 (1999-09-01), pages 351 - 354, XP001098486, ISSN: 0005-9366 *
NEUBAUER ANTONIE ET AL: "Equine herpesvirus 1 mutants devoid of glycoprotein B or M are apathogenic for mice but induce protection against challenge infection", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 239, no. 1, 8 December 1997 (1997-12-08), pages 36 - 45, XP002146619, ISSN: 0042-6822 *
OSTERRIEDER N: "Construction and characterization of an equine herpesvirus 1 glycoprotein C negative mutant.", VIRUS RESEARCH. NETHERLANDS FEB 1999, vol. 59, no. 2, February 1999 (1999-02-01), pages 165 - 177, XP002229839, ISSN: 0168-1702 *
OSTERRIEDER NIKOLAUS ET AL: "Deletion of gene 52 encoding glycoprotein M of equine herpesvirus type 1 strain RacH results in increased immunogenicity.", VETERINARY MICROBIOLOGY, vol. 81, no. 3, 8 August 2001 (2001-08-08), pages 219 - 226, XP002225301, ISSN: 0378-1135 *
RUDOLPH J ET AL: "Cloning of the genomes of equine herpesvirus type 1 (EHV-1) strains KyA and RacL11 as bacterial artificial chromosomes (BAC).", JOURNAL OF VETERINARY MEDICINE SERIES B, vol. 49, no. 1, February 2002 (2002-02-01), February, 2002, pages 31 - 36, XP002213947, ISSN: 0931-1793 *
RUDOLPH JENS ET AL: "Equine herpesvirus type 1 devoid of gM and gp2 is severely impaired in virus egress but not direct cell-to-cell spread.", VIROLOGY, vol. 293, no. 2, 15 February 2002 (2002-02-15), February 15, 2002, pages 356 - 367, XP002225302, ISSN: 0042-6822 *
SCHUMACHER D ET AL: "Reconstitution of Marek's disease virus serotype 1 (MDV-1) from DNA clones as a Bacterial Artificial Chromosome and characterization of a glycoprotein B-negative MDV-1 mutant", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 23, December 2000 (2000-12-01), pages 11088 - 11098, XP002156798, ISSN: 0022-538X *
See also references of EP1377668A2 *
SUTER M ET AL: "BAC-VAC, a novel generation of (DNA) vaccines: a bacterial artificial chromosome containing a replication-competent, packaging-defective virus genome induces protective immunity against herpes simplex virus 1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 22, 26 October 1999 (1999-10-26), pages 12697 - 12702, XP002142150, ISSN: 0027-8424 *
TELFORD E A ET AL: "The DNA sequence of equine herpesvirus-4.", THE JOURNAL OF GENERAL VIROLOGY. ENGLAND MAY 1998, vol. 79 ( Pt 5), May 1998 (1998-05-01), pages 1197 - 1203, XP002225299, ISSN: 0022-1317 *
TELFORD E A R ET AL: "THE DNA SEQUENCE OF EQUINE HERPESVIRUS-1", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 189, no. 1, 1992, pages 304 - 316, XP000886227, ISSN: 0042-6822 *
YI SUN ET AL: "THE ROLE OF THE GENE 71 PRODUCT IN THE LIFE CYCLE OF EQUINE HERPESVIRUS 1", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 77, no. 3, 1 March 1996 (1996-03-01), pages 493 - 500, XP002055346, ISSN: 0022-1317 *

Also Published As

Publication number Publication date
JP2004531254A (en) 2004-10-14
WO2002081712A2 (en) 2002-10-17
EP1377668A2 (en) 2004-01-07
DE10116594A1 (en) 2002-10-10
MXPA03008971A (en) 2004-02-12
CA2443039A1 (en) 2002-10-17
AR035809A1 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
WO2003088994A3 (en) Modified vaccinia virus ankara for the vaccination of neonates
DE69929232D1 (en) VIRUSELY PARTICLES FOR INDUCING AUTOANTIC BODIES
WO2005021707A3 (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
WO2007054279A8 (en) Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
EP1016418A3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
ECSP093601A (en) PROTEINS DERIVED FROM THE WHITE SPOT SYNDROME VIRUS AND ITS USES
WO2005033333A3 (en) Methods and compositions for the diagnosis of cancer
WO2006073431A3 (en) Avipox recombinants expressing foot and mouth disease virus genes
ATE547118T1 (en) RECOMBINANT KOI HERPES VIRUS (KHV) OR CYPRINID HERPES VIRUS 3 (CYHV-3) AND VACCINE FOR PREVENTING DISEASE CAUSED BY KHV/CYHV-3 IN CYPRINUS CARPIO CARPIO OR CYPRINUS CARPIO KOI
MY144492A (en) Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
WO2004085682A3 (en) Caspase inhibitors, especially caspase 3 inhibitors, for the treatment of influenza
MXPA05005202A (en) Vaccine.
DE602004028029D1 (en) Rwendung
WO2002072802A3 (en) Live attenuated strains of prrs virus
WO2004071430A3 (en) RNAi TARGETING OF VIRUSES
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
EP1613345A4 (en) Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
WO2000057909A3 (en) Attenuated dengue-2 virus vaccine
WO2004043404A3 (en) Process for designing inhibitors of influenza virus non-structural protein 1
EP2977457A3 (en) Idna vaccines and methods for using the same
WO2002081712A3 (en) Artificial chromosomes comprising ehv sequences
CY1109206T1 (en) gM- NEGATIVE EHV-MUTALS WITHOUT HARTEROGICAL INFORMATION
WO2000057904A3 (en) Attenuated dengue-3 virus vaccine
TW200509964A (en) VP1 of foot-and-mouth disease virus
WO2004082596A3 (en) Yersinia species compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/008971

Country of ref document: MX

Ref document number: 2443039

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002580075

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002257739

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002727508

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002727508

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002727508

Country of ref document: EP